Clinical Trials Browser

Phase 1 × Inotuzumab Ozogamicin × 90 days × Clear all

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Phase 1 Recruiting

Burkitt Lymphoma, Recurrence

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, B-Cell